CAR T-Cell Therapy in India
Cutting-edge CAR T-cell therapy for relapsed/refractory blood cancers in India. Personalized T-cell immunotherapy for ALL, DLBCL, myeloma, and lymphoma. Expert hematology centers.
Estimated cost: $40,000 – $80,000 · Average stay: 20–30 days
CAR T-cell therapy — chimeric antigen receptor T-cell therapy — represents one of the most significant breakthroughs in cancer immunotherapy in modern medicine. This personalized living drug is created by genetically engineering the patient's own T-cells to recognize and attack cancer cells expressing a specific surface antigen. The resulting CAR T-cells are infused back into the patient, where they multiply and can persist for years, providing durable anti-cancer immunity.
The initial CAR T-cell products targeted CD19 — a protein universally expressed on B-lymphocytes and most B-cell malignancies. Anti-CD19 CAR T-cell therapy (axicabtagene ciloleucel [Yescarta], tisagenlecleucel [Kymriah]) achieves complete remission in approximately 40–60% of patients with relapsed or refractory DLBCL and 70–90% of pediatric and young adult ALL patients — diseases where conventional therapy had largely failed.
The field has since expanded beyond CD19: BCMA-targeted CAR T-cells (ciltacabtagene autoleucel [Carvykti], idecabtagene vicleucel [Abecma]) achieve deep and durable responses in heavily pretreated multiple myeloma. CD20, CD22, CD30, CD38, and other antigens are being targeted in ongoing clinical trials.
India has approved and initiated CAR T-cell therapy programs. NexCAR19 — developed by ImmunoACT (a company spun out of IIT Bombay and Tata Memorial Hospital) — became India's first indigenous CAR T-cell therapy approved in 2023, specifically designed to reduce costs dramatically compared to imported Western CAR T-cell products. Gaf Healthcare coordinates access to CAR T-cell therapy programs in India for eligible international patients.
How CAR T-Cell Therapy Works
CAR T-cell therapy is a five-step personalized process:
Step 1 — Leukapheresis: the patient's blood is passed through an apheresis machine that collects T-cells (white blood cells) from the bloodstream. This takes 3–4 hours and is performed as an outpatient procedure.
Step 2 — Genetic engineering: collected T-cells are sent to a manufacturing facility where they are genetically modified using viral vectors to express the chimeric antigen receptor (CAR) — a synthetic protein that combines an antibody fragment targeting the cancer antigen with T-cell activation domains. This manufacturing process takes 2–4 weeks.
Step 3 — Expansion: the modified CAR T-cells are cultured and expanded to hundreds of millions of cells.
Step 4 — Lymphodepletion: the patient receives 3 days of chemotherapy (fludarabine + cyclophosphamide) to eliminate existing immune cells and make space for the incoming CAR T-cells.
Step 5 — Infusion: the CAR T-cell product is infused back into the patient as a single intravenous infusion. The cells engraft, multiply, and attack CD19-expressing (or other target-expressing) cancer cells, causing rapid tumor clearance.
Cytokine release syndrome (CRS) — caused by massive immune activation — occurs in most patients and is managed with tocilizumab and steroids.
Who Is Eligible for CAR T-Cell Therapy?
CAR T-cell therapy is currently approved and available for specific indications in relapsed/refractory hematologic malignancies:
Anti-CD19 CAR T-cells for B-cell lymphoma: FDA-approved for relapsed/refractory DLBCL, primary mediastinal B-cell lymphoma, and follicular lymphoma after ≥2 prior lines of therapy. Complete remission rates of 40–58% in DLBCL, with durable responses in approximately 30–40% of patients.
Anti-CD19 CAR T-cells for ALL: FDA-approved for relapsed/refractory B-cell ALL in patients up to age 25 years (tisagenlecleucel). Complete remission rates of 70–90% — an extraordinary result in previously untreatable disease. DLBCL response rates in older adults with the same product.
BCMA-targeted CAR T-cells for multiple myeloma: approved for patients who have received at least 3 prior lines of therapy including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Overall response rates of 70–97%; complete response rates of 39–73%. Moving earlier in treatment in ongoing trials.
General eligibility requirements: adequate performance status (ECOG ≤1–2), adequate organ function, no active central nervous system lymphoma involvement (usually), and adequate CD4 count. Prior autologous transplant does not disqualify candidacy.
The CAR T-Cell Therapy Process
The CAR T-cell therapy process from leukapheresis to infusion typically takes 4–6 weeks. During the manufacturing phase, patients may receive bridging chemotherapy to control their disease.
Leukapheresis: performed at the treating center on day 0. An apheresis catheter or large peripheral access is used. T-cells are separated and the remaining blood returned to the patient. The collected cells are cryopreserved and shipped to the manufacturing facility.
Bridging chemotherapy (weeks 1–4): while CAR T-cells are being manufactured, patients receive chemotherapy to control their disease. For DLBCL, platinum-based regimens (R-ICE, R-DHAP) or polatuzumab vedotin + BR are used.
Lymphodepletion chemotherapy (days -5 to -1): fludarabine (25 mg/m²/day × 3 days) + cyclophosphamide (250 mg/m²/day × 3 days) depletes the immune system to create a favorable environment for CAR T-cell expansion.
CAR T-cell infusion (day 0): the thawed product is infused over 30–60 minutes. Patients are hospitalized for 7–14 days for monitoring of CRS and ICANS (immune effector cell-associated neurotoxicity syndrome).
Post-infusion monitoring: daily assessment for CRS (fever, hypotension, hypoxia) and ICANS (confusion, tremor, encephalopathy). Tocilizumab is the primary CRS treatment; steroids for ICANS. Most severe CRS occurs in the first 2 weeks.
Procedure Steps
- Eligibility assessment: performance status, organ function, prior therapy history, and disease burden evaluation.
- Insurance/financial pre-authorization and center certification confirmation.
- Leukapheresis: collection of T-cells via apheresis catheter at the certified center.
- Cell shipment to manufacturing facility and production of CAR T-cell product (2–4 weeks).
- Bridging chemotherapy to control disease during manufacturing.
- Admission: lymphodepletion chemotherapy (fludarabine + cyclophosphamide) for 3 days.
- CAR T-cell infusion (day 0): single IV infusion; ICU availability on standby for Grade 3–4 CRS.
- Post-infusion hospitalization: 7–14 days monitoring for CRS and ICANS; tocilizumab and steroids as needed.
CAR T-Cell Therapy Approaches
Anti-CD19 CAR T (DLBCL / Aggressive NHL)
Axicabtagene ciloleucel (Yescarta) or tisagenlecleucel (Kymriah) for relapsed/refractory DLBCL and other aggressive B-cell lymphomas. Complete response rates of 40–58%; durable responses in ~30–40%. NexCAR19 (India's indigenous product) approved for DLBCL and ALL at significantly reduced cost.
Cost: $40,000 – $80,000 (imported); $30,000 – $50,000 (NexCAR19)
Anti-CD19 CAR T (Pediatric ALL)
Tisagenlecleucel for relapsed/refractory B-cell ALL in patients ≤25 years. Complete remission rates of 70–90% — transformative in this otherwise difficult disease. Long-term event-free survival of approximately 50% at 24 months.
Cost: $40,000 – $80,000
BCMA CAR T (Multiple Myeloma)
Ciltacabtagene autoleucel (Carvykti) or idecabtagene vicleucel (Abecma) for heavily pretreated multiple myeloma. Overall response rates of 70–97%; complete response 39–73%. Increasingly moving earlier in treatment lines based on CARTITUDE-4 trial data.
Cost: $50,000 – $90,000
NexCAR19 (India's Indigenous CAR T)
India's first approved CAR T-cell therapy, developed by ImmunoACT from IIT Bombay and Tata Memorial Hospital. Targets CD19. Approved for relapsed/refractory B-cell ALL and DLBCL. Priced at approximately 40–60% less than imported products, making CAR T accessible to a far wider population.
Cost: $30,000 – $50,000
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
India (NexCAR19) — $30,000 – $50,000 — Save 50–75%
India (imported) — $40,000 – $80,000 — Save 30–60%
USA / Europe — $450,000 – $650,000+ — Baseline
CAR T-cell therapy costs $450,000–$650,000+ in the United States. India's indigenous NexCAR19 product — the first locally manufactured CAR T approved for clinical use in any developing country — is available at $30,000–$50,000, making potentially curative treatment for relapsed lymphoma and ALL accessible to international patients at a fraction of Western costs. Gaf Healthcare identifies centers where NexCAR19 and imported CAR T products are available.
Recovery & Follow-up
After CAR T-cell infusion, patients are monitored in hospital for 7–14 days. Cytokine release syndrome (CRS) — fever, hypotension, sometimes requiring ICU care — occurs in most patients and peaks at days 2–7, responding to tocilizumab in the majority. ICANS (confusion, tremor) is managed with steroids. After hospital discharge, patients remain near the treatment center for an additional 4 weeks for outpatient monitoring. Full immune reconstitution takes 6–12 months; prophylactic antibiotics and IVIG replacement are required during this period.
Recovery Tips
- Report any fever, confusion, or difficulty speaking immediately after CAR T infusion — these are the earliest signs of CRS or ICANS requiring prompt treatment.
- Do not drive or operate heavy machinery for at least 8 weeks after CAR T — ICANS can cause sudden neurological symptoms.
- Prophylactic antiviral (acyclovir) and antifungal (fluconazole) medications must be taken as prescribed during immune reconstitution.
- Avoid live vaccines for 12 months after CAR T therapy — the immune system requires time to recover fully.
- The first PET-CT at day +28–+30 provides the initial response assessment — this is the most critical early indicator of treatment success.
Risks & Complications
Cytokine release syndrome (CRS): occurs in 70–90% of patients; severe (grade 3–4) in 10–25%. Managed with tocilizumab and steroids; ICU care occasionally required. ICANS: occurs in 20–60%; encephalopathy, seizure, and cerebral edema in rare severe cases. B-cell aplasia: lasting months to years after anti-CD19 CAR T; managed with IVIG. Infections: prolonged immunosuppression increases risk; pneumocystis and herpes prophylaxis required. Prolonged cytopenias: may require growth factor support or transfusions.
Why GAF Healthcare
Gaf Healthcare is one of the few medical tourism coordinators actively working with India's CAR T-cell therapy programs. We connect eligible international patients with certified CAR T centers, coordinate the complete process from leukapheresis to infusion and post-infusion monitoring, and facilitate access to India's indigenous NexCAR19 product — which provides a transformative price advantage that makes this potentially curative therapy accessible to patients worldwide.
Frequently Asked Questions
What is CAR T-cell therapy and how is it different from other cancer treatments?
CAR T-cell therapy uses the patient's own T-cells, genetically engineered to recognize specific cancer proteins, and reinfused as a living drug that attacks cancer cells. Unlike chemotherapy (which kills rapidly dividing cells non-specifically) or targeted therapy (small molecules), CAR T-cells are living cells that can multiply and persist in the body, providing ongoing immune surveillance. Complete remissions lasting years have been documented.
Am I eligible for CAR T-cell therapy?
Eligibility depends on your diagnosis, number of prior therapies, performance status, and organ function. Currently approved indications include: relapsed/refractory DLBCL (≥2 prior lines), relapsed/refractory B-ALL in patients ≤25 years, and heavily pretreated multiple myeloma (≥3 prior lines). Gaf Healthcare can arrange rapid eligibility assessment by India's CAR T centers within 48–72 hours of receiving your medical records.
What is NexCAR19 and why is it special?
NexCAR19 is India's first indigenously developed and approved CAR T-cell therapy product. It was developed at IIT Bombay in collaboration with Tata Memorial Hospital through the company ImmunoACT. It targets CD19 for B-cell lymphoma and ALL. Its significance: it is approved for clinical use at approximately $30,000–$50,000 — compared to $450,000–$650,000 for imported Western products — potentially making CAR T-cell therapy accessible to patients globally.
How long does the CAR T-cell therapy process take?
From leukapheresis to CAR T infusion takes approximately 4–6 weeks (manufacturing time). Add 7–14 days of post-infusion hospitalization. Then 4 more weeks of outpatient monitoring required near the treatment center. Total time commitment in India: approximately 10–12 weeks. After this, follow-up can be coordinated with your local oncologist.
What is cytokine release syndrome (CRS)?
CRS occurs when CAR T-cells rapidly expand and kill cancer cells, releasing large amounts of inflammatory cytokines into the bloodstream. Symptoms include: fever (universal), fatigue, low blood pressure, and in severe cases respiratory failure. Grade 1–2 CRS (most patients) is managed with monitoring and supportive care. Grade 3–4 CRS is treated with tocilizumab — a targeted anti-IL-6 antibody — with excellent results. Most centers have established protocols that effectively manage CRS safely.